Kanamycin
Kantrex, Klebcil (kanamycin) is a small molecule pharmaceutical. Kanamycin was first approved as Kantrex on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, escherichia coli infections, hepatic encephalopathy, and klebsiella infections amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acinetobacter infections | EFO_1000792 | D000151 | — |
| bacterial infections | — | D001424 | A49 |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| hepatic encephalopathy | — | D006501 | K72.91 |
| klebsiella infections | EFO_1001353 | D007710 | — |
| mycobacterium infections | — | D009164 | A31.9 |
| proteus infections | EFO_1001130 | D011512 | — |
| respiratory tract infections | — | D012141 | J06.9 |
| serratia infections | EFO_1001421 | D016868 | — |
| staphylococcal infections | — | D013203 | A49.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA08: Kanamycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB04: Kanamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA24: Kanamycin
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney calculi | D007669 | EFO_0004253 | N20.0 | — | 2 | 1 | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | 1 | 2 |
| Orthostatic intolerance | D054971 | 1 | — | — | — | 1 | 2 | ||
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Orthostatic hypotension | D007024 | I95.1 | 1 | — | — | — | — | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Vasodilation | D014664 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | — | — | — | — | 2 | 2 | |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | — | — | 2 | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | — | — | — | 1 | 1 |
| Primary dysautonomias | D054969 | — | — | — | — | 1 | 1 | ||
| Intraoperative awareness | D058926 | — | — | — | — | 1 | 1 | ||
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | KANAMYCIN |
| INN | kanamycin |
| Description | Kanamycin A is a member of kanamycins. It has a role as a bacterial metabolite. It is a conjugate base of a kanamycin A(4+). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 59-01-8 |
| RxCUI | 1727573 |
| ChEMBL ID | CHEMBL1384 |
| ChEBI ID | 17630 |
| PubChem CID | 6032 |
| DrugBank | DB01172 |
| UNII ID | RUC37XUP2P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000009631 | MT-RNR1 | drug response | 2021-06-15 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 109,821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
251 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more